小程序掃碼下單
本網(wǎng)站銷(xiāo)售的所有產(chǎn)品僅用于工業(yè)應(yīng)用或者科學(xué)研究等非醫(yī)療目的，不可用于人類(lèi)或動(dòng)物的臨床診斷或者治療，非藥用，非食用。
維多珠單抗
英文名：Vedolizumab
Cas號(hào)：943609-66-3
Cas號(hào)：943609-66-3
檢測(cè)信息查詢(xún)
| 貨號(hào) | 規(guī)格 | 貨期 | 庫(kù)存 | 價(jià)格 | 促銷(xiāo)價(jià) | 訂購(gòu) |
| 13081324921-1mg | 99.64% | 0 | ￥5800 | |||
| 13081324921-5mg | 99.64% | 0 | ￥17600 |
| 別 名 | |
| Cas號(hào) | 943609-66-3 |
| M D L | |
| 分子式 | |
| 分子量 | |
| 產(chǎn)品參數(shù) | Description
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease. IC50 & Target Integrin[1] Storage Please store the product under the recommended conditions in the Certificate of Analysis. |
| 性狀 | Vedolizumab是一種靶向α4β7整聯(lián)蛋白 (integrin) 的人源化單克隆抗體，用來(lái)治療潰瘍性結(jié)腸炎和克羅恩病。 |
| 貯存 | References [1]. Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. [2]. Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7( |
滬公網(wǎng)安備 31012002003054號(hào)